Cryoport stock faces estimated November 3 earnings report

Published on 10/17/2026 at 20:22 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter revenue reached USD 48.97 million, up 8.00 percent. Cryoport stock closed at USD 16.84 on October 16, 2026, down 1.35 percent on Nasdaq.

Upcoming report and stock metrics

MarketBeat estimates the next Cryoport earnings report for November 3, 2026.
Second-quarter revenue reached USD 48.97 million on June 30, 2026.
Cryoport stock closed at USD 16.84 on Nasdaq on October 16, 2026, down 1.35 percent versus the prior close of USD 17.07.
Cryoport's market capitalization was USD 852.9 million on October 16, 2026.

CYRX, US2290503075, Illustration mit AI erstellt.

MarketBeat estimates Cryoport's next earnings report for November 3, 2026, after the market close, with a conference call scheduled for 5:00 p.m. ET. Cryoport stock had closed at USD 16.84 on Nasdaq on October 16, 2026, down 1.35 percent from the prior close of USD 17.07.

Second-quarter revenue grew

Investing.com reported that Cryoport generated USD 49.00 million in second-quarter revenue and USD 0.40 million in adjusted EBITDA. The company's Life Sciences Services business contributed 57.00 percent of sales and grew 15.00 percent year over year, while full-year revenue guidance remained USD 192.00 million to USD 196.00 million.

Price position on Nasdaq

MetaCap placed the October 16 closing price at USD 16.84, with a session range of USD 16.66 to USD 17.14 and volume of 509,034 shares against an average of 629,775 shares. The stock stood 8.28 percent below its 52-week high of USD 18.36 and 121.29 percent above its 52-week low of USD 7.61. Year to date, Cryoport was up 75.40 percent as of October 16, 2026.

Valuation and dividend profile

Cryoport's market capitalization was USD 852.9 million on October 16, 2026. MetaCap reported no regular cash dividend and described the trailing price-to-earnings ratio as not meaningful because the company had a net loss over the last twelve months. The November 3 report is expected to cover the third quarter of 2026; MarketBeat lists consensus earnings per share of minus USD 0.19 and revenue of USD 48.69 million.

Comparison with peers

CYRX (Nasdaq, USD): minus 1.35 percent, market capitalization USD 852.9 million.
Alto Neuroscience (Nasdaq, USD): minus 3.01 percent, market capitalization USD 861.0 million.
Rigel Pharmaceuticals (Nasdaq, USD): minus 2.71 percent, price-to-earnings ratio 2.70, market capitalization USD 858.7 million.

Market context for the stock

Cryoport provides temperature-controlled logistics, biostorage and cryopreservation services for life sciences companies. The company reported second-quarter 2026 revenue of USD 48.97 million and a net loss of USD 8.26 million for the quarter ended June 30, 2026.

On October 16, 2026, Cryoport stock closed at USD 16.84 on Nasdaq at 4:00 p.m. ET, down 1.35 percent from the prior close of USD 17.07. The next scheduled reporting date is November 3, 2026.